A KD modulates leptin, ghrelin, and melatonin plasma levels and gene expression in the brain, which suggests that these endocrine regulatory molecules have neuroprotective or antiepileptic effects in epilepsy and serve as potential markers of antiepileptic drug responses (12, 13). The gene discussed is LEP; the disease is epilepsy.